Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
Jacob Chacko, insider at ORIC Pharmaceuticals

Jacob Chacko Insider Information

Dr. Chacko was most recently CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. During his tenure, the company grew from fewer than 20 employees and a $50 million enterprise value to 125 employees and a $1.7 billion enterprise value at the time of acquisition. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company.

Dr. Chacko currently serves on the board of directors of 4D Molecular Therapeutics (Nasdaq: FDMT) and chairs the Western Regional Selection Committee for the Marshall Scholarship. He previously served on the board of directors of Turning Point Therapeutics (Nasdaq: TPTX), Bonti (acquired by Allergan), EnvisionRx (acquired by Rite Aid), RentPath, and the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford; and he was a board observer to Par Pharmaceutical (acquired by Endo), IMS Health and Quintiles Transnational.

Dr. Chacko concurrently received his MD with AOA honors from UCLA and his MBA with Distinction from Harvard Business School. He also received a MSc from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian.

What is Jacob Chacko's net worth?

The estimated net worth of Jacob Chacko is at least $2.21 million as of May 11th, 2022. Dr. Chacko owns 657,226 shares of ORIC Pharmaceuticals stock worth more than $2,214,852 as of May 22nd. This net worth estimate does not reflect any other investments that Dr. Chacko may own. Additionally, Dr. Chacko receives a salary of $883,680.00 as CEO at ORIC Pharmaceuticals. Learn More about Jacob Chacko's net worth.

How old is Jacob Chacko?

Dr. Chacko is currently 43 years old. There are 8 older executives and no younger executives at ORIC Pharmaceuticals. Learn More on Jacob Chacko's age.

What is Jacob Chacko's salary?

As the CEO of ORIC Pharmaceuticals, Inc., Dr. Chacko earned a total compensation package of $5,873,786.00 in 2020. Dr. Chacko earned a salary of $489,167.00, options awards of $5,082,831.00, non-equity compensation of $300,800.00, and other compensation of $988.00. Learn More on Jacob Chacko's salary.

How do I contact Jacob Chacko?

The corporate mailing address for Dr. Chacko and other ORIC Pharmaceuticals executives is 240 E. GRAND AVE. 2ND FLOOR, SOUTH SAN FRANCISCO CA, 94080. ORIC Pharmaceuticals can also be reached via phone at 650-388-5600 and via email at [email protected] Learn More on Jacob Chacko's contact information.

Has Jacob Chacko been buying or selling shares of ORIC Pharmaceuticals?

During the past quarter, Jacob Chacko has bought $1,097,787.64 in shares of ORIC Pharmaceuticals stock. Most recently, 0 shares of the stock in a transaction dated Sunday, May 22nd. Learn More on Jacob Chacko's trading history.

Who are ORIC Pharmaceuticals' active insiders?

ORIC Pharmaceuticals' insider roster includes Jacob Chacko (CEO), Carl Gordon (Director), Richard Heyman (Director), and Richard Scheller (Director). Learn More on ORIC Pharmaceuticals' active insiders.

Are insiders buying or selling shares of ORIC Pharmaceuticals?

During the last twelve months, ORIC Pharmaceuticals insiders bought shares 5 times. They purchased a total of 747,773 shares worth more than $2,926,880.10. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 17,364 shares worth more than $435,428.21. The most recent insider tranaction occured on May, 13th when CEO Jacob Chacko bought 76,072 shares worth more than $214,523.04. Insiders at ORIC Pharmaceuticals own 24.6 % of the company. Learn More about insider trades at ORIC Pharmaceuticals.

Information on this page was last updated on 5/13/2022.

Jacob Chacko Insider Trading History at ORIC Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2022Buy76,072$2.82$214,523.04802,652View SEC Filing Icon  
5/11/2022Buy304,574$2.90$883,264.60657,226View SEC Filing Icon  
3/25/2022Buy50,000$4.54$227,000.00View SEC Filing Icon  
3/23/2022Buy257,127$4.98$1,280,492.46View SEC Filing Icon  
9/15/2021Sell3,736$25.06$93,624.166,388View SEC Filing Icon  
9/13/2021Sell2,801$25.02$70,081.026,388View SEC Filing Icon  
9/10/2021Sell2,942$25.08$73,785.36View SEC Filing Icon  
9/7/2021Sell5,981$25.11$150,182.9116,751View SEC Filing Icon  
5/24/2021Sell12$25.00$300.0027,934View SEC Filing Icon  
5/20/2021Sell2,468$25.07$61,872.7627,934View SEC Filing Icon  
5/13/2021Sell730$25.04$18,279.2059,310View SEC Filing Icon  
5/11/2021Sell1,090$25.22$27,489.8059,310View SEC Filing Icon  
4/30/2021Sell1,300$25.14$32,682.0061,000View SEC Filing Icon  
4/28/2021Sell700$25.06$17,542.0061,000View SEC Filing Icon  
4/1/2021Sell800$25.09$20,072.0061,700View SEC Filing Icon  
See Full Table

Jacob Chacko Buying and Selling Activity at ORIC Pharmaceuticals

This chart shows Jacob Chacko's buying and selling at ORIC Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ORIC Pharmaceuticals Company Overview

ORIC Pharmaceuticals logo
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $3.37
Low: $3.14
High: $3.46

50 Day Range

MA: $4.51
Low: $2.70
High: $7.07

2 Week Range

Now: $3.37
Low: $2.62
High: $26.70


170,162 shs

Average Volume

489,537 shs

Market Capitalization

$133.05 million

P/E Ratio


Dividend Yield



Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.